Spatial distribution of G6PD deficiency variants across malaria-endemic regions

Rosalind E Howes, Mewahyu Dewi, Frédéric B Piel, Wuelton M Monteiro, Katherine E Battle, Jane P Messina, Anavaj Sakuntabhai, Ari W Satyagraha, Thomas N Williams, J Kevin Baird, Simon I Hay, Rosalind E Howes, Mewahyu Dewi, Frédéric B Piel, Wuelton M Monteiro, Katherine E Battle, Jane P Messina, Anavaj Sakuntabhai, Ari W Satyagraha, Thomas N Williams, J Kevin Baird, Simon I Hay

Abstract

Background: Primaquine is essential for malaria control and elimination since it is the only available drug preventing multiple clinical attacks by relapses of Plasmodium vivax. It is also the only therapy against the sexual stages of Plasmodium falciparum infectious to mosquitoes, and is thus useful in preventing malaria transmission. However, the difficulties of diagnosing glucose-6-phosphate dehydrogenase deficiency (G6PDd) greatly hinder primaquine's widespread use, as this common genetic disorder makes patients susceptible to potentially severe and fatal primaquine-induced haemolysis. The risk of such an outcome varies widely among G6PD gene variants.

Methods: A literature review was conducted to identify surveys of G6PD variant frequencies among representative population groups. Informative surveys were assembled into two map series: (1) those showing the relative proportions of the different variants among G6PDd individuals; and (2) those showing allele frequencies of G6PD variants based on population surveys without prior G6PDd screening.

Results: Variants showed conspicuous geographic patterns. A limited repertoire of variants was tested for across sub-Saharan Africa, which nevertheless indicated low genetic heterogeneity predominated by the G6PD A(-202A) mutation, though other mutations were common in western Africa. The severe G6PD Mediterranean variant was widespread across western Asia. Further east, a sharp shift in variants was identified, with high variant heterogeneity in the populations of China and the Asia-Pacific where no single variant dominated.

Conclusions: G6PD variants exhibited distinctive region-specific distributions with important primaquine policy implications. Relative homogeneity in the Americas, Africa, and western Asia contrasted sharply with the heterogeneity of variants in China, Southeast Asia and Oceania. These findings will inform rational risk assessments for primaquine in developing public health strategies for malaria control and elimination, and support the future development of regionally targeted policies. The major knowledge gaps highlighted here strongly advocate for further investigation of G6PD variant diversity and their primaquine-sensitivity phenotypes.

Figures

Figure 1
Figure 1
Survey inclusion criteria and G6PDd variant map outputs. Orange rectangles indicate the exclusion criteria, grey hexagons summarize the two final input data, and green rods represent the two map types.
Figure 2
Figure 2
G6PDd variant proportion map: Americas (map series 1). Map includes nine surveys with a mean sample size of 71 (range: 8-196); one survey was mapped at the national level. Pie charts represent individuals previously identified as G6PDd. Sample size is reflected in the size of the pie charts, which is transformed for clarity on a square-root scale. Surveys which could only be mapped to the country-level are indicated by a white star; this applied to seven surveys globally. Spatial duplicates from independent studies were mapped with a “jitter” of 0.5-1 decimal degrees in their latitude or longitude coordinates to allow visualization of the multiple charts. Malaria-endemic countries in the region mapped are shown with a yellow background; white backgrounds indicate endemic countries outside the region in focus; grey backgrounds represent malaria-free countries. G6PDd variants that could not be diagnosed were reported as “Other”.
Figure 3
Figure 3
G6PDd variant proportion map: Africa+ (map series 1). Map includes six surveys with a mean sample size of 43 (range: 5-110). One survey was mapped at the national level. (See Figure  2 for full legend).
Figure 4
Figure 4
G6PDd variant proportion map: Asia (map series 1). Map includes 87 surveys with a mean sample size of 53 (range: 1-532). Four surveys were mapped to the national level. (See Figure  2 for full legend).
Figure 5
Figure 5
G6PDd variant proportion map: West Asia (map series 1). A higher resolution map of Figure  4.
Figure 6
Figure 6
G6PDd variant proportion map: East Asia (map series 1). A higher resolution map of Figure  4.
Figure 7
Figure 7
G6PDd variant proportion map: Asia-Pacific (map series 1). Panel A show the full map, which includes 36 surveys with a mean sample size of 18 (range: 1-128). One survey was mapped at the national level. The East Nusa Tenggara province islands identified by the dotted box are shown at higher resolution in Panel B. (See Figure  2 for full legend).
Figure 8
Figure 8
G6PD A- variant SNP frequency map for Africa (map series 2). Bar charts representing the frequencies of G6PD variants. The variants that were tested for in each location are listed above the x-axis. Empty spaces along the x-axis indicate that the named variant was tested for but not identified in the population sample. Survey locations are mapped to closest approximation at the point of origin of the plots and exact locations shown in Additional file 4. Sample size is listed under each plot. Equivalent maps of the Americas and Asia are Additional files 3 and 5.

References

    1. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124:484–485.
    1. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339. doi: 10.1371/journal.pmed.1001339.
    1. The malERA Consultative Group on Diagnoses and Diagnostics. A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med. 2011;8:e1000396.
    1. Baird JK, Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011;27:11–16. doi: 10.1016/j.pt.2010.08.005.
    1. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36–57. doi: 10.1128/CMR.00074-12.
    1. Baird JK. Reinventing primaquine for endemic malaria. Expet Opin Emerg Drugs. 2012;17:439–444. doi: 10.1517/14728214.2012.720252.
    1. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7(Suppl 1):S8. doi: 10.1186/1475-2875-7-S1-S8.
    1. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.
    1. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297. doi: 10.1186/1475-2875-10-297.
    1. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377–410. doi: 10.1128/CMR.00051-10.
    1. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2012;13:175–181.
    1. WHO. Guidelines for the treatment of malaria, second edition. Geneva: World Health Organization; 2010.
    1. WHO. Global plan for artemisinin resistance containment (GPARC) Geneva: WHO; 2011.
    1. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418. doi: 10.1186/1475-2875-11-418.
    1. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS One. 2012;7:e37166. doi: 10.1371/journal.pone.0037166.
    1. Greene LS. G6PD deficiency as protection against falciparum-malaria: an epidemiologic critique of population and experimental studies. Yearb Phys Anthropol. 1993;36:153–178. doi: 10.1002/ajpa.1330360609.
    1. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005;77:171–192. doi: 10.1086/432519.
    1. Beutler E. G6PD: population genetics and clinical manifestations. Blood Rev. 1996;10:45–52. doi: 10.1016/S0268-960X(96)90019-3.
    1. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555–566. doi: 10.1016/S1473-3099(09)70177-X.
    1. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74. doi: 10.1016/S0140-6736(08)60073-2.
    1. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: Global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133–201.
    1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ. et al.Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–2223. doi: 10.1016/S0140-6736(12)61689-4.
    1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M. et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0.
    1. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis. 2012;55:e67–e74. doi: 10.1093/cid/cis615.
    1. Luzzatto L. In: Nathan and Oski’s Hematology of Infancy and Childhood. 7. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, editor. Philadelphia: Saunders; 2009. Glucose-6-phosphate dehydrogenase deficiency.
    1. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the "old" and update of the new mutations. Blood Cells Mol Dis. 2012;48:154–165. doi: 10.1016/j.bcmd.2012.01.001.
    1. Mason PJ, Vulliamy TJ. Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, Ltd; 2005. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: genetics.
    1. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601–611.
    1. Yoshida A, Beutler E, Motulsky AG. Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ. 1971;45:243–253.
    1. Hockwald RS, Arnold J, Clayman CB, Alving AS. Toxicity of primaquine in Negroes. JAMA. 1952;149:1568–1570. doi: 10.1001/jama.1952.72930340027010c.
    1. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 1991;324:169–174. doi: 10.1056/NEJM199101173240306.
    1. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44:171–176.
    1. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22:621–631.
    1. Cavalli-Sforza LL, Menozzi P, Piazza A. The History and Geography of Human Genes. Princeton, New Jersey: Princeton University Press; 1994.
    1. Piomelli S, Corash LM, Davenport DD, Miraglia J, Amorosi EL. In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and GdMediterranean deficiency. J Clin Invest. 1968;47:940–948. doi: 10.1172/JCI105786.
    1. Meloni T, Forteleoni G, Dore A, Cutillo S. Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient subjects in North Sardinia. Acta Haematol. 1983;70:83–90. doi: 10.1159/000206700.
    1. Luisada A. Favism. JAMA. 1940. pp. 632–632.
    1. Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779–789.
    1. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 1981;59:391–395.
    1. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health. 2001;32:720–726.
    1. Matsuoka H, Wang J, Hirai M, Arai M, Yoshida S, Kobayashi T, Jalloh A, Lin K, Kawamoto F. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Myanmar: G6PD Mahidol (487G > A) is the most common variant in the Myanmar population. J Hum Genet. 2004;49:544–547. doi: 10.1007/s10038-004-0187-7.
    1. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546–1549. doi: 10.1126/science.1178849.
    1. Burgoine KL, Bancone G, Nosten F. The reality of using primaquine. Malar J. 2010;9:376. doi: 10.1186/1475-2875-9-376.
    1. Laosombat V, Sattayasevana B, Chotsampancharoen T, Wongchanchailert M. Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children. Int J Hematol. 2006;83:139–143. doi: 10.1532/IJH97.A20513.
    1. Baird JK. Elimination therapy for the endemic malarias. Curr Infect Dis Rep. 2012;14:227–237. doi: 10.1007/s11908-012-0250-z.
    1. Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007;21:267–283. doi: 10.1016/j.blre.2007.05.002.
    1. Mourant AE, Kopec AC, Domaniewska-Sobczak K. The distribution of the human blood groups and other polymorphisms. London: Oxford University Press; 1976.
    1. Livingstone FB. Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants and ovalocytosis in human populations. New York: Oxford University Press; 1985.
    1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42:267–278. doi: 10.1016/j.bcmd.2008.12.005.
    1. Singh S. Distribution of certain polymorphic traits in populations of the Indian peninsula and South Asia. Isr J Med Sci. 1973;9:1225–1237.
    1. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378. doi: 10.1186/1475-2875-10-378.
    1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HFL, Price RN, Mueller I, Baird JK, Hay SI. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814. doi: 10.1371/journal.pntd.0001814.
    1. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria CW, Manh BH, Elyazar IR, Brooker S, Smith DL, Moyeed RA, Snow RW. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 2009;6:e1000048.
    1. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI. The global public health significance of Plasmodium vivax. Adv Parasitol. 2012;80:1–111.
    1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004;4:327–336. doi: 10.1016/S1473-3099(04)01043-6.
    1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97–106.
    1. Singh H, Parakh A, Basu S, Rath B. Plasmodium vivax malaria: is it actually benign? J Infect Pub Health. 2011;4:91–95. doi: 10.1016/j.jiph.2011.03.002.
    1. Mahgoub H, Gasim GI, Musa IR, Adam I. Severe Plasmodium vivax malaria among Sudanese children at New Halfa Hospital, Eastern Sudan. Parasit Vectors. 2012;5:154. doi: 10.1186/1756-3305-5-154.
    1. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612–620. doi: 10.1093/cid/ciq249.
    1. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J. 2010;9:254. doi: 10.1186/1475-2875-9-254.
    1. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, Von Seidlein L, Drakeley C. On behalf of the Primaquine in Africa Discussion Group. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J. 2012;11:360. doi: 10.1186/1475-2875-11-360.
    1. Malaria Policy Advisory Committee Meeting. WHO Evidence Review Group Report: the safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. Geneva: World Health Organization; 2012.
    1. Global Malaria Programme WHO. Updated WHO Policy Recommendation: Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2012.
    1. Edgcomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L, Jeffery GM, Eyles D, Young MD. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285–292.
    1. Alving AS, Hankey DD, Coatney GR, Jones R Jr, Coker WG, Garrison PL, Donovan WN. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg. 1953;2:970–976.
    1. Coatney GR, Alving AS, Jones R Jr, Hankey DD, Robinson DH, Garrison PL, Coker WG, Donovan WN, Di Lorenzo A, Marx RL, Simmons IH. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg. 1953;2:985–988.
    1. Flanagan CL, Schrier SL, Carson PE, Alving AS. The hemolytic effect of primaquine. VIII. The effect of drug administration on parameters of primaquine sensitivity. J Lab Clin Med. 1958;51:600–608.
    1. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14:103–139.
    1. Alving AS, Craige B, Pullman TN, Whorton CM, Jones R, Eichelberger L. Procedures used at Stateville Penitentiary for the testing of potential antimalarial agents. J Clin Invest. 1948;27:2–5. doi: 10.1172/JCI101956.
    1. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010;54:1762–1768. doi: 10.1128/AAC.01135-09.
    1. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet. 2010;376:739–741. doi: 10.1016/S0140-6736(10)60396-0.
    1. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120:4123–4133. doi: 10.1182/blood-2012-03-416032.
    1. Galiano S, Gaetani GF, Barabino A, Cottafava F, Zeitlin H, Town M, Luzzatto L. Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-) BMJ. 1990;300:236.
    1. Mehta AB. Glucose-6-phosphate dehydrogenase deficiency. Postgrad Med J. 1994;70:871–877. doi: 10.1136/pgmj.70.830.871.
    1. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, Richardson A, Teo YY, Small K, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Sabeti P, Kwiatkowski DP, Rockett KA. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet. 2009;17:1080–1085. doi: 10.1038/ejhg.2009.8.
    1. 1000 Genomes - A Deep Catalog of Human Genetic Variation. .
    1. International HapMap Project. .
    1. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, Zimmerman PA, Barnadas C, Beall CM, Gebremedhin A, Menard D, Williams TN, Weatherall DJ, Hay SI. The global distribution of the Duffy blood group. Nat Commun. 2011;2:266.
    1. WHO. World Malaria Report 2012. Geneva: World Health Organization; 2012.
    1. Boyd MF. An Introduction to Malariology. Cambridge, MA: Harvard University Press; 1930.
    1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774. doi: 10.1371/journal.pntd.0000774.
    1. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am J Trop Med Hyg. 2006;75:575–581.
    1. Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, Takeo S, Tsuboi T, Yadava A, Carter R, Tanabe K. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis. 2009;200:1465–1469. doi: 10.1086/644510.
    1. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V, Carod JF, Domarle O, Colin Y, Bertrand O, Picot J, King CL, Grimberg BT, Mercereau-Puijalon O, Zimmerman PA. Plasmodium vivax clinical malaria is commonly observed in duffy-negative malagasy people. Proc Natl Acad Sci USA. 2010;107:5967–5971. doi: 10.1073/pnas.0912496107.
    1. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, De Sousa B, Do Rosario VE, Benito A, Berzosa P, Arez AP. Duffy negative antigen is no longer a barrier to plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea) PLoS Negl Trop Dis. 2011;5:e1192. doi: 10.1371/journal.pntd.0001192.
    1. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S. Vivax malaria in mauritania includes infection of a duffy-negative individual. Malar J. 2011;10:336. doi: 10.1186/1475-2875-10-336.
    1. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW. Shrinking the malaria map: progress and prospects. Lancet. 2010;376:1566–1578. doi: 10.1016/S0140-6736(10)61270-6.
    1. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382(9895):900–911. doi: 10.1016/S0140-6736(13)60310-4.
    1. UCSF Global Health Group and Malaria Atlas Project. Atlas of Malaria-Eliminating Countries. University of California, San Francisco: The Global Health Group, Global Health Sciences; 2011.
    1. Hay SI, Gething PW, Snow RW. India’s invisible malaria burden. Lancet. 2010;376:1716–1717. doi: 10.1016/S0140-6736(10)61084-7.
    1. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, O’Brien J, Djimde A, Doumbo O, Zongo I, Ouedraogo JB, Michon P, Mueller I, Siba P, Nzila A, Borrmann S, Kiara SM, Marsh K, Jiang H, Su XZ, Amaratunga C, Fairhurst R, Socheat D, Nosten F, Imwong M, White NJ, Sanders M, Anastasi E, Alcock D, Drury E. et al.Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature. 2012;487:375–379. doi: 10.1038/nature11174.
    1. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Day NP, Singhasivanon P. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J. 2010;9:308. doi: 10.1186/1475-2875-9-308.
    1. Myat Phone K, Myint O, Aung N, Aye Lwin H. The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. Southeast Asian J Trop Med Public Health. 1994;25:710–713.
    1. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J. 2010;9:57. doi: 10.1186/1475-2875-9-57.

Source: PubMed

3
Subskrybuj